Grifols (GIFLF) Change in Acquisitions & Divestments (2012 - 2013)
Grifols' (GIFLF) quarterly Change in Acquisitions & Divestments came in at $69415.6 in Q4 2013, up 103.05% on a YoY basis from $34186.8 in Q4 2012, and down 99.5% quarter-over-quarter from $13.8 million in Q3 2013.
Powered by 
Analysis
Grifols (GIFLF) Change in Acquisitions & Divestments (2012 - 2013) Analysis & Trends
Grifols (GIFLF) has reported Change in Acquisitions & Divestments for 2 consecutive years, with $69415.6 the latest figure, recorded in Q4 2013.
- For the quarter ending Q4 2013, Change in Acquisitions & Divestments rose 103.05% year-over-year to $69415.6; the trailing twelve-month figure through Dec 2013 stood at $48.7 million (changed N/A YoY), and the FY2025 full-year result was $10.2 million, down 99.4% from the prior year.
- Change in Acquisitions & Divestments eased to $69415.6 in Q4 2013 per GIFLF's latest filing, from $13.8 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $37.1 million in Q3 2012 and bottomed at -$2.3 million in Q4 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2013 | 69,415.57 |
| Sep 30, 2013 | 13.85 Mn |
| Dec 31, 2012 | -2.28 Mn |
| Sep 30, 2012 | 37.06 Mn |